Skip to content

Homeopathic medicines for treatment of psoriasis

Efficacy of individualized homeopathic medicines in treatment of psoriasis vulgaris: Double-blind, randomized, placebo-controlled clinical trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/11/021917
Enrollment
60
Registered
2019-11-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Individualized homeopathic medicines in 50 millesimal potencies: Intervention is planned as administering individualized homeopathic medicines in 50 millesimal potencies, as decided app
16 doses to be marked on the vial

Sponsors

National Institute of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients suffering from mild to moderate psoriasis (PASI score 20 or less) for 3 months or more 2. Age between 18-65 years 3. Both sexes 4. Patient willing to take part in the study and giving written consent 5. Literate patients; ability to read English and/or Bengali

Exclusion criteria

Exclusion criteria: 1. Severe psoriasis (PASI score more than 20) 2. Patient who are too sick for consultation 3. Unable to read patient information sheets and not giving consent to take part 4. Psoriasis with complications like erythroderma and pustules 5. Diagnosed cases of unstable psychiatric illness or other systemic disease affecting quality of life 6. Currently receiving homeopathic treatment for chronic condition(s) 7. Pregnant and lactating women 8. Self-reported immune-compromised state 9. Substance abuse and/or dependence

Design outcomes

Primary

MeasureTime frame
Psoriasis Area Scoring Index (PASI)Timepoint: Baseline, every 2 months, up to 6 months

Secondary

MeasureTime frame
Dermatological Life Quality Index (DLQI) questionnaire scoreTimepoint: Baseline, every 2 months, up to 6 months;Psoriasis Disability Index (PDI) questionnaire scoreTimepoint: Baseline, every 2 months, up to 6 months

Countries

India

Contacts

Public ContactChintamani Nayak

National Institute of Homoeopathy

drcnayak@gmail.com9433161854

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026